{
    "clinical_study": {
        "@rank": "85535", 
        "arm_group": [
            {
                "arm_group_label": "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 5.0 \u00b5g GLA-AF", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 5.0 \u00b5g GLA-AF", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Hookworms digest hemoglobin from erythrocytes for use as an energy source via a proteolytic\n      cascade that begins with the aspartic protease, APR-1.  Vaccination with recombinant APR-1\n      has protected animals from infection in challenge studies.  This study will evaluate the\n      safety and immunogenicity of two formulations of Na-APR-1 (M74) in healthy adult volunteers\n      when co-administered with different concentrations of the immunostimulant GLA-AF."
        }, 
        "brief_title": "Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hookworm Infection", 
            "Hookworm Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hookworm Infections", 
                "Ancylostomiasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Open-label, dose-escalation phase 1 clinical trial in healthy, hookworm-na\u00efve adults:\n\n        -  Study site: George Washington Medical Faculty Associates, Washington, DC\n\n        -  Number of participants: 40 in 2 cohorts of 20.\n\n      In Cohort 1 five (5) volunteers will receive 30 \u00b5g Na-APR-1 (M74) /Alhydrogel\u00ae, five (5)\n      will receive 30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF, and ten (10) will receive\n      30 \u00b5g Na-APR-1 (M74) /Alhydrogel\u00ae plus 5 \u00b5g GLA-AF. In Cohort 2 five (5) volunteers will\n      receive 100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae, five (5) will receive 100 \u00b5g Na-APR-1 (M74)\n      /Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF, and ten (10) will receive 100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae\n      plus 5 \u00b5g GLA-AF.\n\n      The cohorts will be enrolled in a staggered fashion with safety data assessed prior to the\n      Na-APR-1 dose escalation from 30 to 100 \u00b5g. In addition, within each cohort, vaccinations\n      will be staggered such that formulations containing 0, 2.5, and 5 \u00b5g GLA-AF will be tested\n      sequentially: for example, those receiving Na-APR-1 (M74)/Alhydrogel\u00ae in combination with\n      2.5 \u00b5g GLA-AF will be vaccinated no sooner than 3 days after the last volunteer is\n      vaccinated with the formulation containing no GLA-AF, whereas those vaccinated with Na-APR-1\n      (M74)/Alhydrogel\u00ae plus 5 \u00b5g GLA-AF will be vaccinated no sooner than 7 days after the last\n      one receives the 2.5 \u00b5g GLA-AF formulation.\n\n        -  Immunization schedule: Study days 0, 56 and 112.\n\n        -  Route: IM in the deltoid muscle.\n\n        -  Doses of Na-APR-1 (M74) to be tested: 30 and 100 \u00b5g.\n\n        -  Doses of Alhydrogel\u00ae: 240 and 800 \u00b5g for the 30 and 100 \u00b5g doses of Na-APR-1 (M74),\n           respectively.\n\n        -  Doses of GLA-AF to be tested: 2.5 \u00b5g and 5 \u00b5g.\n\n        -  Study duration: 44 weeks (10 months) per study participant; total duration of the study\n           estimated at approximately 13 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females between 18 and 50 years, inclusive.\n\n          -  Good general health as determined by means of the screening procedure.\n\n          -  Available for the duration of the trial (44 weeks).\n\n          -  Willingness to participate in the study as evidenced by signing the informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if\n             female).\n\n          -  Participant unwilling to use reliable contraception methods up until one month\n             following the third immunization (if female and not surgically sterile, abstinent or\n             at least 2 years post-menopausal).\n\n          -  Currently lactating and breast-feeding (if female).\n\n          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,\n             rheumatologic, autoimmune, diabetes, or renal disease by history, physical\n             examination, and/or laboratory studies.\n\n          -  Known or suspected immunodeficiency.\n\n          -  Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than\n             1.25-times the upper reference limit).\n\n          -  Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the\n             upper reference limit, or more than trace protein or blood on urine dipstick\n             testing).\n\n          -  Laboratory evidence of hematologic disease (hemoglobin <11.5 g/dl [females] or <12.5\n             g/dl [males]; absolute leukocyte count <3600/mm3 or >10.7 x 103/mm3; absolute\n             neutrophil count [ANC] <1700/ mm3; absolute lymphocyte count <700/mm3; or platelet\n             count <140,000/mm3).\n\n          -  Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper\n             reference limit).\n\n          -  Serum glucose (random) greater than 1.2-times the upper reference limit.\n\n          -  Other condition that in the opinion of the investigator would jeopardize the safety\n             or rights of a volunteer participating in the trial or would render the subject\n             unable to comply with the protocol.\n\n          -  Participation in another investigational vaccine or drug trial within 30 days of\n             starting this study.\n\n          -  Volunteer has had medical, occupational, or family problems as a result of alcohol or\n             illicit drug use during the past 12 months.\n\n          -  History of a severe allergic reaction or anaphylaxis.\n\n          -  Severe asthma as defined by the need for daily use of inhalers or emergency clinic\n             visit or hospitalization within 6 months of the volunteer's expected first\n             vaccination in the study.\n\n          -  Positive ELISA for hepatitis B surface antigen (HBsAg).\n\n          -  Positive confirmatory test for HIV infection.\n\n          -  Positive confirmatory test for hepatitis C virus (HCV) infection.\n\n          -  Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within\n             30 days of the volunteer's expected first vaccination in this study.\n\n          -  Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to\n             the volunteer's expected first vaccination in the study.\n\n          -  History of a surgical splenectomy.\n\n          -  Receipt of blood products within the past 6 months.\n\n          -  History of previous infection with hookworm or residence for more than 6 months in a\n             hookworm-endemic area."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717950", 
            "org_study_id": "SVI-12-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae", 
                    "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF", 
                    "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 5.0 \u00b5g GLA-AF", 
                    "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae", 
                    "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF", 
                    "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 5.0 \u00b5g GLA-AF"
                ], 
                "description": "The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel\u00ae) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 \u00b1 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel\u00ae is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.", 
                "intervention_name": "Na-APR-1 (M74)/Alhydrogel\u00ae", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Na-APR-1", 
                    "Necator americanus Aspartic Protease-1"
                ]
            }, 
            {
                "arm_group_label": [
                    "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF", 
                    "30 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 5.0 \u00b5g GLA-AF", 
                    "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 2.5 \u00b5g GLA-AF", 
                    "100 \u00b5g Na-APR-1 (M74)/Alhydrogel\u00ae plus 5.0 \u00b5g GLA-AF"
                ], 
                "description": "GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.", 
                "intervention_name": "Gluco-Pyranosylphospho-Lipid A Aqueous Formulation", 
                "intervention_type": "Biological", 
                "other_name": "GLA-AF"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aluminum Hydroxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Human Hookworm", 
            "Necator americanus", 
            "Hookworm", 
            "Hookworm Disease", 
            "Iron-deficiency anemia", 
            "Soil-transmitted helminth infection", 
            "Neglected Tropical Disease", 
            "Na-APR-1"
        ], 
        "lastchanged_date": "March 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20036"
                }, 
                "name": "George Washington University Medical Faculty Associates"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel\u00ae in Healthy Adults", 
        "overall_official": {
            "affiliation": "George Washington University", 
            "last_name": "David J Diemert, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequency of immediate, systemic, and local injection site adverse events will be summarized.  Adverse events will be assessed by study team members at 1 hour post-vaccination as well as 3, 7, 14, and 28 days following each vaccination.  In addition, study participants will be asked to complete symptom diaries for the 7 days after each vaccination.", 
            "measure": "Vaccine-related Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Day 290"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Dose and formulation of Na-APR-1 that generates the highest IgG antibody response at Day 126 (14 days after final vaccination), as determined by an indirect enzyme-linked immunosorbent assay (ELISA).", 
                "measure": "IgG antibody response to Na-APR-1", 
                "safety_issue": "No", 
                "time_frame": "14 days after final vaccination"
            }, 
            {
                "description": "Dose and formulation of the Na-APR-1 (M74) vaccine that results in the highest production of Na-APR-1 (M74) specific B cells and subtypes (memory or plasma).", 
                "measure": "B cell response to Na-APR-1", 
                "safety_issue": "No", 
                "time_frame": "Study Days 14, 70, 126, 140 and 290"
            }, 
            {
                "description": "Exploratory studies of the cellular immune responses to the Na APR-1 (M74) antigen both before and after immunization.", 
                "measure": "Exploratory cellular immune response to Na-APR-1", 
                "safety_issue": "No", 
                "time_frame": "Study Days 14, 70, 126, 140 and 290"
            }
        ], 
        "source": "Albert B. Sabin Vaccine Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "George Washington University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Albert B. Sabin Vaccine Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}